Daniel J Starks

CIK 902132 · Chairman, CEO & President · last filed 2026-04-28

Daniel J Starks is a Chairman, CEO & President who has filed 85 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for ABT, was dated Apr 28, 2026. Across all open-market trades the lifetime net is −$171.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $658.3M across reported positions. 25 SEC filings were submitted jointly with Laboratories Abbott.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$658.26M

Companies

Total Filings

Lifetime Open-Market Net

-$171.17M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address

ONE ST JUDE MEDICAL DRIVE
ST PAUL, MN 55117

Related Filers

Laboratories Abbott — 25 joint filings, latest 2026-04-28

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
ABT	Director	6,751,361	$97.50	$658.26M	-$25.67M	21	2026-04-28
ST JUDE MEDICAL, LLC (STJ) Delisted	Chairman, CEO & President	6,319,888	—	—	-$145.50M	58	2016-12-20
UROLOGIX INC (ULGX) Delisted	Director	30,000	—	—	$0	2	2008-11-13

Recent Filings

85 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-04-28	ABT	Mixed	+12,286	$926.5K	EDGAR
2026-02-06	ABT	Buy (P)	+10,000	$1.09M	EDGAR
2025-04-29	ABT	Grant (A)	+1,635	$0	EDGAR
2024-04-30	ABT	Grant (A)	+1,866	$0	EDGAR
2023-10-30	ABT	Sell (S)	−50,000	-$4.70M	EDGAR
2023-10-26	ABT	Notice (144)	−50,000	-$4.65M	EDGAR
2023-07-28	ABT	Sell (S)	−50,000	-$5.69M	EDGAR
2023-07-27	ABT	Notice (144)	−50,000	-$5.69M	EDGAR
2023-05-02	ABT	Notice (144)	−50,000	-$5.55M	EDGAR
2023-05-02	ABT	Mixed	−48,184	-$5.55M	EDGAR

Showing 1–10 of 85

Page 1 of 9 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.